Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results...
Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
Fosun Pharma (SHA: 600196; HKG: 2196) announced it has signed a Memorandum of Cooperation with...
Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has...
Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a strategic partnership with Sun...
Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform
Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and...
Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801
Vivacta Biotechnology, a Shanghai-based in vivo chimeric antigen receptor (CAR)-T therapy developer, announced the successful...
Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis
Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced it has received...
Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB...
Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required
Immunotech Biopharm Ltd. (HKG: 6978), a chimeric antigen receptor T-cell (CAR-T) specialist based in China,...
GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma
GluBio Pharmaceutical Co., Ltd., a molecular glue targeted protein degradation (TPD) specialist based in Zhejiang,...
Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European...
AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise
AbbVie Inc. (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to...
Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform
Medtronic plc (NYSE: MDT) announced it has received CE Mark approval for the Stealth AXiS...
Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements
Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals,...
Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
Santo Therapeutics, a Hangzhou-based in vivo gene therapy developer, announced it has received both Orphan...
Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
Johnson & Johnson (J&J, NYSE: JNJ) announced that its supplemental Biologics License Application (sBLA) for...
AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
AbbVie (NYSE: ABBV) announced it has submitted a marketing approval filing to the U.S. Food...
GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational...
Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Prothena Corporation plc (NASDAQ: PRTA) announced that the U.S. Food and Drug Administration (FDA) has...
Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”
Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered...